HopeStage
Back to all studies
CompletedNCT00852202

Cariprazine for depression in bipolarity

About this title

Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar Depression

Read the official source — NCT00852202

Researchers compared cariprazine and placebo to find out how the approaches affected depression symptoms in people with bipolarity during a depressive episode.

Medication studyAges 18–65United States
The study in practice

Understand this study

What did researchers investigate?

Researchers compared cariprazine and placebo to find out how the approaches affected depression symptoms in people with bipolarity during a depressive episode.

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Encino and 25 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: June 30, 2009
Recruitment status
Completed
Enrollment listed in the registry
234
Sponsor
Forest Laboratories
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT00852202
Official title
Show the full official title

A Double-blind, Placebo-controlled Study of RGH-188 (Cariprazine) in Bipolar Depression

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Encino · Garden Grove · National City

23 more locations
  • Newport Beach
  • Oceanside
  • Bradenton
  • Jacksonville
  • Kissimmee
  • Orlando
  • West Palm Beach
  • Glen Burnie
  • Creve Coeur
  • Omaha
  • Cherry Hill
  • The Bronx
  • Durham
  • Dayton
  • Mason
  • Portland
  • Media
  • Philadelphia
  • Nashville
  • Irving
  • Woodstock
  • Bellevue
  • Seattle

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers compared cariprazine and placebo to find out how the approaches affected depression symptoms in people with bipolarity during a depressive episode.

Who is behind this study?

The study sponsor is Forest Laboratories, a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including cariprazine and placebo.

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies